Hubei Goto Biopharm Co Ltd
SZSE:300966
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.7), the stock would be worth ¥20.57 (18% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.3 | ¥25.01 |
0%
|
| 3-Year Average | 2.7 | ¥20.57 |
-18%
|
| 5-Year Average | 2.9 | ¥22.13 |
-12%
|
| Industry Average | 4.2 | ¥31.47 |
+26%
|
| Country Average | 2.4 | ¥18.51 |
-26%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Hubei Goto Biopharm Co Ltd
SZSE:300966
|
2.9B CNY | 3.3 | -62.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | -114.2 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 21.5 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 7.2 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 5.8 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 2.4 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 6.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.2 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Hubei Goto Biopharm Co Ltd
Glance View
Hubei Goto Biopharm Co., Ltd. engages in the research, development, production, and sale of steroidal drug raw materials. The company is headquartered in Xiangfan, Hubei and currently employs 481 full-time employees. The company went IPO on 2021-04-09. The firm's main products are starting materials and intermediates required for the production of steroid drugs. The starting materials refer to the products obtained from the conversion of plant sterols through biological fermentation technology. These products are important raw materials for downstream pharmaceutical intermediates and active pharmaceutical ingredient manufacturers and belong to the upstream products in the steroid drug industry chain. The firm's intermediate products mainly include sex hormone intermediates, progesterone intermediates, corticosteroid intermediates and other products.
